mTOR: An attractive therapeutic target for osteosarcoma?

Oncotarget. 2016 Aug 2;7(31):50805-50813. doi: 10.18632/oncotarget.9305.

Abstract

Osteosarcoma (OS) is a common primary malignant bone tumor with high morbidity and mortality in children and young adults. How to improve poor prognosis of OS due to resistance to chemotherapy remains a challenge. Recently, growing findings show activation of mammalian target of rapamycin (mTOR), is associated with OS cell growth, proliferation, metastasis. Targeting mTOR may be a promising therapeutic approach for treating OS. This review summarizes the roles of mTOR pathway in OS and present research status of mTOR inhibitors in the context of OS. In addition, we have attempted to discuss how to design a better treatment project for OS by combining mTOR inhibitor with other drugs.

Keywords: apoptosis; autophagy; mTOR; osteosarcoma; target.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / chemistry
  • Apoptosis
  • Autophagy
  • Bone Neoplasms / diagnosis
  • Bone Neoplasms / drug therapy*
  • Bone Neoplasms / metabolism*
  • Cell Enlargement
  • Cell Proliferation
  • Humans
  • Neoplasm Metastasis
  • Osteosarcoma / diagnosis
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / metabolism*
  • Prognosis
  • TOR Serine-Threonine Kinases / metabolism*

Substances

  • Antineoplastic Agents
  • MTOR protein, human
  • TOR Serine-Threonine Kinases